Demodex Blepharitis

Two down, one to go.

Demodex blepharitis is so common that it makes up more than twothirds of all blepharitis cases.

The FDA approved Xdemvy, a 0.25% lotilaner ophthalmic solution, for the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.

Healio spoke with I. Paul Singh, MD, about recent new treatment options in dry eye.

Healio spoke with Leslie O’Dell, OD, FAAO, medical director and director of clinical research at Medical Optometry America in Shrewsbury, about research needs and upcoming treatment options for patients with dry eye disease.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Laura M. Periman, MD, discusses slit lamp investigation techniques to more effectively scan for Demodex blepharitis.

In these videos, Preeya K. Gupta, MD, FACS, associate professor of ophthalmology at Duke University, talks about the various treatment options for dry eye, both approved and in the pipeline, as well as challenges in diagnosis.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

NEW YORK — In a Healio Video Perspective from OSN New York, Aziz Mottiwala, of Tarsus Pharmaceuticals, discusses the FDA acceptance of the new drug application for TP-03 for the treatment of Demodex blepharitis.